이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Rhinomed 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Michael Johnson

최고 경영자

AU$531.6k

총 보상

CEO 급여 비율	69.8%
CEO 임기	11yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	5.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Michael Johnson 의 보수는 Rhinomed 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2023	AU$532k	AU$371k	-AU$11m
Mar 31 2023	n/a	n/a	-AU$9m
Dec 31 2022	n/a	n/a	-AU$7m
Sep 30 2022	n/a	n/a	-AU$6m
Jun 30 2022	AU$369k	AU$301k	-AU$5m
Mar 31 2022	n/a	n/a	-AU$6m
Dec 31 2021	n/a	n/a	-AU$6m
Sep 30 2021	n/a	n/a	-AU$8m
Jun 30 2021	AU$2m	AU$304k	-AU$9m
Mar 31 2021	n/a	n/a	-AU$8m
Dec 31 2020	n/a	n/a	-AU$7m
Sep 30 2020	n/a	n/a	-AU$7m
Jun 30 2020	AU$1m	AU$304k	-AU$7m
Mar 31 2020	n/a	n/a	-AU$8m
Dec 31 2019	n/a	n/a	-AU$8m
Sep 30 2019	n/a	n/a	-AU$7m
Jun 30 2019	AU$748k	AU$305k	-AU$6m
Mar 31 2019	n/a	n/a	-AU$5m
Dec 31 2018	n/a	n/a	-AU$5m
Sep 30 2018	n/a	n/a	-AU$5m
Jun 30 2018	AU$363k	AU$255k	-AU$4m
Mar 31 2018	n/a	n/a	-AU$4m
Dec 31 2017	n/a	n/a	-AU$5m
Sep 30 2017	n/a	n/a	-AU$5m
Jun 30 2017	AU$672k	AU$231k	-AU$4m

보상 대 시장: Michael 의 총 보상 ($USD 347.11K )은 Australian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 298.77K ).

보상과 수익: 회사가 수익성이 없는 동안 Michael 의 보상이 증가했습니다.

CEO

Michael Johnson

11yrs

테뉴어

AU$531,600

보상

Mr. Michael Johnson serves as the Chief Executive Officer, Managing Director and Executive Director of Rhinomed Limited (formerly, Consegna Group Limited) since February 1, 2013. Mr. Johnson serves as a Di...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Michael Johnson	CEO, MD & Executive Director	11yrs	AU$531.60k	0.64% A$ 73.9k
Ross MacDonald	Member of the Medical Advisory Board	no data	데이터 없음	데이터 없음
Ronald Dewhurst	Independent Non-Executive Chairman	8.2yrs	AU$110.00k	6.88% A$ 792.3k
Steve Harris	Member of the Medical Advisory Board	no data	데이터 없음	데이터 없음
Lynette Swinburne	Non-Executive Director	1.4yrs	AU$58.45k	0.062% A$ 7.1k
John McBain	Non-Executive Director	2.8yrs	AU$73.33k	18.43% A$ 2.1m

5.5yrs

평균 재임 기간

경험이 풍부한 이사회: RNO 의 이사회는 경험(평균 재직 기간 5.5 년)으로 간주됩니다.

Rhinomed 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Less than half of directors are independent

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Less than half of directors are independent

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Less than half of directors are independent

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Less than half of directors are independent

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

Less than half of directors are independent

New major risk - Market cap size

Less than half of directors are independent

Insider recently bought AU$242k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Insider recently bought AU$372k worth of stock

Less than half of directors are independent

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간